Literature DB >> 1968547

Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up.

D M van der Heijde, P L van Riel, I H Nuver-Zwart, L B van de Putte.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1968547     DOI： 10.1016/0140-6736(90)90771-v

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

Review 1.  From The Netherlands.

Authors:  A Cats; F C Breedveld
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

2.  Assessment of the treat-to-target strategy in patients with refractory rheumatoid arthritis. A prospective study on efficacy and safety in a Saudi population.

Authors:  R H A Mohammed; H H Kewan; M Bukhari
Journal:  Z Rheumatol       Date:  2014-10       Impact factor: 1.372

Review 3.  Sulfasalazine: a review of its use in the management of rheumatoid arthritis.

Authors:  Greg L Plosker; Katherine F Croom
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis.

Authors:  H A Capell; M Brzeski
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

Review 5.  Disease modifying drugs for rheumatoid arthritis: yesterday's treatment today or today's treatment tomorrow?

Authors:  T Pullar
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

6.  Early treatment of rheumatoid arthritis: rationale, evidence, and implications.

Authors:  L B van de Putte; A M van Gestel; P L van Riel
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

Review 7.  Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Nat Rev Rheumatol       Date:  2015-02-17       Impact factor: 20.543

8.  A T cell receptor beta chain variable region polymorphism associated with radiographic progression in rheumatoid arthritis.

Authors:  N de Vries; C F Prinsen; E B Mensink; P L van Riel; M A van't Hof; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

Review 9.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

10.  Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy.

Authors:  T Möttönen; L Paimela; M Leirisalo-Repo; H Kautiainen; J Ilonen; P Hannonen
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.